
Aurinia Pharmaceuticals Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Aurinia Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases, most notably its drug voclosporin (marketed as Lupkynis), an oral treatment approved for lupus nephritis, a kidney complication of systemic lupus erythematosus.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Robertson Stephen P.Chief Legal Officer | Sell | $356K | 20,975at $16.97 | Aug 21, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable AUPH activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.